Tavlesse 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0014 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
09/09/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0012 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/08/2022 
n/a 
Veterinary Medicinal Products - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
PSUSA/10819
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
fostamatinib 
N/0010 
Minor change in labelling or package leaflet not 
10/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10819
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202104 
fostamatinib 
IB/0009 
B.II.b.1.z - Replacement or addition of a 
24/08/2021 
n/a 
manufacturing site for the FP - Other variation 
PSUSA/10819
Periodic Safety Update EU Single assessment - 
24/06/2021 
18/08/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202010 
fostamatinib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10819/202010. 
IB/0006/G 
This was an application for a group of variations. 
08/03/2021 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
PSUSA/10819
Periodic Safety Update EU Single assessment - 
29/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202004 
fostamatinib 
N/0005 
Minor change in labelling or package leaflet not 
23/09/2020 
n/a 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0003/G 
This was an application for a group of variations. 
22/06/2020 
17/06/2021 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0002 
Transfer of Marketing Authorisation 
12/03/2020 
01/04/2020 
SmPC, 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labelling and 
PL 
Page 4/4 
 
 
 
 
 
 
 
